In this review:
Recurrent pericarditis and pericardial effusion during pembrolizumab use
Knowledge, attitudes and practices regarding medicinal cannabis among Australians with cancer
Estimating survival in older chemotherapy recipients
Antibiotic use within 30 days of immune checkpoint inhibitors: impact on response
Immune checkpoint inhibitorrelated acquired demyelinating polyneuropathy
Anti-PMNA2 and anti-NMDA receptor antibody-positive pembrolizumabinduced encephalitis
Dose modifications for haematological toxicity
Dose modifications for taxane chemotherapy-induced peripheral neuropathy
NLR changes during first-line immunotherapy for metastatic melanoma are associated with outcome
Resource use for case discussions at cancer MDMs
Please login below to download this issue (PDF)